$ARDX News

Will Ardelyx (ARDX) Report Negative Earnings Next Week? What You Should Know

New Cross-Study Analysis from Spherix Global Insights Combines Physician, Dietitian and Patient Chart Data to Show Access Barriers Still Curbing Xphozah Uptake Ahead of the TDAPA Cliff

Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026

Claude AI Says Market is Ignoring Ardelyx (ARDX) Growth Catalysts

Ardelyx: The Market Is Right To Discount This Revenue Growth

ARDX Stock Tumbles As Xphozah Loses Final Medicare Reimbursement Battle

Ardelyx Stock Up 70%: What to Know About This $490,000 Insider Transaction

What’s Fueling Optimism Around Ardelyx, Inc. (ARDX)’s Sales and Pipeline?

Ladenburg Thalmann Assumes Ardelyx at Buy, Announces Price Target of $16

Ardelyx (ARDX) Stock Valuation Check After Recent Share Price Volatility

Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach

ARDX Edges Up After Hours On IBSRELA Momentum And Profitability ‘Right Around The Corner’

Should You Buy Ardelyx (ARDX)?

Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026

Ardelyx (ARDX) Is Up 10.3% After Long-Term XPHOZAH Safety Data In Dialysis Patients - What's Changed

Ardelyx: Low Price, But High Implied Valuation

Assessing Ardelyx (ARDX) Valuation After Q1 2026 Results And Reaffirmed Revenue Guidance

Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings

Ardelyx Presents Data Analysis Evaluating Long-Term Impact Of XPHOZAH On Serum Electrolytes And Selected Nutrition Biomarkers At The National Kidney Foundation Meetings

Analyst Estimates: Here's What Brokers Think Of Ardelyx, Inc. (NASDAQ:ARDX) After Its First-Quarter Report